Key clinical point: Vedolizumab showed superior histological outcomes than adalimumab in patients with moderate-to-severe ulcerative colitis (UC).
Major finding: At 52 weeks, vedolizumab induced greater histologic remission (Robarts Histology Index [RHI], 2 or lower; Δ, 17.6%; P less than .0001) and minimal histologic disease activity (RHI, 4 or lower; Δ, 16.6%; P less than .0001) than adalimumab. Findings were similar in both antitumor necrosis factor-naive and -failure subgroups.
Study details: VARSITY, a phase 3b trial included 769 adult patients with moderately to severely active UC randomly assigned to intravenous vedolizumab or subcutaneous adalimumab.
Disclosures: This study was funded by Takeda. Some of the authors declared receiving grant support, personal fees, consultancy, and/or lecture fees from various sources. R Rogers, RA Lirio, JD Bornstein, and J Chen declared being employees and holding stocks of Takeda.
Source: Peyrin-Biroulet L et al. Gastroenterology. 2021 Jun 15. doi: 10.1053/j.gastro.2021.06.015 .
